NasdaqGM · Biotechnology

Turn Therapeutics Inc. (TTRX)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+174.8%

$26.00 average target

$9.46-0.08 (-0.8%)Latest market snapshot · Yahoo Finance

Market cap$287.3M

Cash$10.3M

Quarterly burn—

Pipeline assets2

Short float0.5%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 174.8% upsideTargets are estimates—not guarantees—and can change after company updates.

$26.00Average target

Wall Street consensus

Strong BuyBased on 1 analyst opinions

1ratings

Buy 1Hold 0Sell 0

Price-target range

$26.00

+174.8%

Low $26.00High $26.00

CurrentAverage

Bear case$26.00+174.8%

Base case$26.00+174.8%

Bull case$26.00+174.8%

Analyst coverage1published opinions

Bullish share100%buy recommendations

Target spread$0low-to-high dispersion

Consensus score1.01.0 is strongest

Recommendation mix

Current rating breakdown

1 tracked ratings

Company profile

About Turn Therapeutics Inc.

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.